Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.5564
+0.066413.55%
Volume:2.53M
Turnover:1.46M
Market Cap:10.38M
PE:-0.93
High:0.6499
Open:0.5890
Low:0.5021
Close:0.4900
52wk High:2.80
52wk Low:0.3679
Shares:18.65M
Float Shares:15.47M
Volume Ratio:24.85
T/O Rate:16.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5992
EPS(LYR):-0.8255
ROE:-178.46%
ROA:-106.58%
PB:2.18
PE(LYR):-0.67

Loading ...

Nexalin announces continued advancement toward trial evaluating HALO Clarity

TIPRANKS
·
Yesterday

BRIEF-Nexalin Announces Pivotal Halo™ Clarity Trial

Reuters
·
Yesterday

Nexalin Announces Pivotal Halo™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

THOMSON REUTERS
·
Yesterday

EXCLUSIVE: Penny Stock Nexalin Advances Pivotal Trial Aiming To Tackle Severe Insomnia

Benzinga_recent_news
·
Yesterday

Nuix Ltd. (NXL) was upgraded to a Buy Rating at RBC Capital

TIPRANKS
·
Feb 23

Nexalin ‘commended’ recent Congressional initiative on neurostim research

TIPRANKS
·
Feb 23

Should You Think About Buying Nuix Limited (ASX:NXL) Now?

Simply Wall St.
·
Feb 13

Nexalin Technology Partners with UC San Diego to Launch AI-Driven NeuroCare Virtual Clinic

Reuters
·
Feb 05

Nexalin Technology highlights research validating neurostimulation technology

TIPRANKS
·
Feb 02

RBC Capital Reaffirms Their Hold Rating on Nuix Ltd. (NXL)

TIPRANKS
·
Jan 31

BRIEF-Nexalin Technology Receives Nasdaq Listing Status Notification

Reuters
·
Jan 24

Nexalin Technology Neurostimulation Device Shows Significant ADHD Symptom Improvement in Clinical Study

Reuters
·
Jan 14

Nexalin Advances Non-Invasive Alzheimer's Therapy Toward FDA Clinical Trials

Reuters
·
Dec 03, 2025

BRIEF-Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync

Reuters
·
Dec 03, 2025

Nexalin Technology Inc - Potential De Novo Pathway Discussed for Nexalin's Technology

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc - Reviewed Endpoints for Alzheimer's Outcomes Including Cognitive Assessments

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc - Plans U.S. Pilot and Pivotal Studies for Gen-2 Sync

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 Sync™ Neurostimulation Console in Alzheimer’s Disease Program

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc: Intends to Incorporate FDA's Feedback From Q-Sub Meeting Into Its Final Pilot Study Protocol

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Hosts Live Investor Webinar Showcasing Mental Health Innovations

Reuters
·
Dec 02, 2025